Company Overview
About Rakuten Medical
Rakuten Medical, Inc. is a biotechnology company founded by Yoshihiro Seto in 2006 (as Aspyrian Therapeutics, renamed Rakuten Medical after acquisition by Rakuten Group) and headquartered in San Diego, California, with primary R&D and commercial operations in Japan. The company is focused on developing cancer treatments using its proprietary photoimmunotherapy (PIT) platform, branded as Illuminox. Photoimmunotherapy combines a targeted antibody conjugated to a photoabsorber dye that, when activated by near-infrared light, selectively destroys cancer cells in the illuminated region while minimizing damage to surrounding healthy tissue — a precision oncology approach distinct from traditional chemotherapy or immunotherapy.
Business Model & Competitive Advantage
Rakuten Medical's lead product, cetuximab sarotalocan (commercial name: Akalux in Japan), received conditional approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in September 2020 for the treatment of unresectable locally advanced or recurrent head and neck cancer — making it the world's first approved photoimmunotherapy cancer treatment. This represents a landmark regulatory achievement for the company and for the broader PIT field. Akalux is commercialized in Japan through partnerships with major oncology centers and continues to accumulate real-world evidence post-approval.
Competitive Landscape 2025–2026
Rakuten Medical is listed on the Tokyo Stock Exchange under the ticker 4707 and is majority-backed by Rakuten Group, the Japanese e-commerce and financial services conglomerate, which provides financial support and brand association. The company is conducting multiple clinical trials globally — including Phase II/III studies in the United States, Europe, and Asia — expanding the indication base for photoimmunotherapy to other cancer types beyond head and neck. Pipeline programs targeting additional solid tumors represent the primary long-term value driver, with the company investing heavily in clinical development to achieve regulatory approvals outside Japan.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Rakuten Medical with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Rakuten Medical? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Rakuten Medical Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Rakuten Medical vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →